Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism
CHEST · 2024-03 · 165 (3) · 673-681
DOI: 10.1016/j.chest.2023.09.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2024-03. Verfasst von Deisy Barrios und 15 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Department, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, S…. Hauptthemen laut MEDLINE: Pulmonary Embolism, COVID-19. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: American Heart Association, VIVA Foundation for Children with Cancer, Rajavithi Hospital.
Abstract (Originalsprache)
BACKGROUND: The effect of supplemental oxygen therapy in patients with intermediate-risk pulmonary embolism (PE) who do not have hypoxemia at baseline is uncertain. RESEARCH QUESTION: Does supplemental oxygen improve echocardiographic parameters in nonhypoxemic patients with intermediate-risk PE? STUDY DESIGN AND METHODS: This pilot trial randomly assigned nonhypoxemic patients with stable PE and echocardiographic right ventricle (RV) enlargement to receive anticoagulation plus supplemental oxygen for the first 48 h vs anticoagulation alone. The primary outcome was normal echocardiographic RV size 48 h after randomization. Secondary efficacy outcomes were the numerical change in the RV to left ventricle (LV) diameter ratio measured 48 h and 7 days after randomization with respect to the baseline ratio measured at inclusion. RESULTS: The study was stopped prematurely because of the COVID-19 pandemic after recruiting 70 patients (mean ± SD age, 67.3 ± 16.1 years; 36 female [51.4%]) with primary outcome data. Forty-eight h after randomization, normalization of the RV size occurred in 14 of the 33 patients (42.4%) assigned to oxygen and in eight of the 37 patients (21.6%) assigned to ambient air (P = .08). In the oxygen group, the mean RV to LV ratio was reduced from 1.28 ± 0.28 at baseline to 1.01 ± 0.16 at 48 h (P < .001); in the ambient air group, mean RV to LV ratios were 1.21 ± 0.18 at baseline and 1.08 ± 0.19 at 48 h (P < .01). At 90 days, one major bleeding event and one death (both in the ambient air group) had occurred. INTERPRETATION: In analyses limited by a small number of enrollees, compared with ambient air, supplemental oxygen did not significantly increase the proportion of patients with nonhypoxemic intermediate-risk PE whose RV to LV ratio normalized after 48 h of treatment. This pilot trial showed improvement in some ancillary efficacy outcomes and provides support for a definitive clinical outcomes trial. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04003116; URL: www. CLINICALTRIALS: gov.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Department, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
- Respiratory Department, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain.
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Respiratory Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Respiratory Department, Hospital de Araba, Vitoria, Spain.
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Respiratory Department, Hospital La Fe, Valencia, Spain.
- Respiratory Department, Hospital Galdakao-Usansolo, Bilbao, Spain.
Förderung
- American Heart Association
- VIVA Foundation for Children with Cancer
- Rajavithi Hospital
- Instituto de Salud Carlos III
Zitieren
APA
Barrios, D., Durán, D., Rodríguez, C., Moisés, J., Retegui, A., Lobo, J. L., López, R., Chasco, L., Jara-Palomares, L., Muriel, A., Otero-Candelera, R., Ruiz-Artacho, P., Monreal, M., Bikdeli, B., Jiménez, D., & Air vs Oxygen for Intermediate-Risk Pulmonary Embolism Investigators (2024). Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism. CHEST, 165(3), 673-681. https://doi.org/10.1016/j.chest.2023.09.007
Vancouver
Barrios D, Durán D, Rodríguez C, Moisés J, Retegui A, Lobo JL, et al. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism. CHEST. 2024;165(3):673-681. doi:10.1016/j.chest.2023.09.007
BibTeX
@article{Barrios2024,
author = {Barrios, Deisy and Durán, Diego and Rodríguez, Carmen and Moisés, Jorge and Retegui, Ana and Lobo, José Luis and López, Raquel and Chasco, Leyre and Jara-Palomares, Luis and Muriel, Alfonso and Otero-Candelera, Remedios and Ruiz-Artacho, Pedro and Monreal, Manuel and Bikdeli, Behnood and Jiménez, David and Air vs Oxygen for Intermediate-Risk Pulmonary Embolism Investigators, Air vs Oxygen for Intermediate-Risk Pulmonary Embolism Investigators},
title = {Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism},
journal = {CHEST},
year = {2024},
volume = {165},
number = {3},
pages = {673--681},
doi = {10.1016/j.chest.2023.09.007}
}
EUVIMED